GlucoTrack, Inc.

Oct 22, 2026

▼ -6.3%on this news· ran to -37% by day 1

Glucotrack, Inc. Announces Reverse Stock Split

Glucotrack, Inc. announced a reverse stock split from its offices in Rutherford, N.J., and La Jolla, Calif. The company provided no further details on the split ratio or its strategic rationale. Investors received no specific information regarding the financial impact of this corporate action. The announcement was brief and lacked explanatory context for the market.

Glucotrack, Inc. Announces Pricing of $3 Million Public Offering

Glucotrack, Inc. has announced the pricing of a public offering of 169,388 shares at $2.04 each, along with pre-funded warrants for additional shares. The offering is expected to generate approximately $3.1 million in gross proceeds and is set to close around September 25, 2026, pending customary conditions. Dawson James Securities is the sole placement agent for this offering.

Sep 23, 2026

▼ -8.6%on this news· ran to -19% by day 3shared move

Lōkahi Therapeutics™ and Glucotrack CEO Erik Emerson Provides Strategic Update on LT-100, ai² Platform Growth and Clinical Development Priorities

Lōkahi Therapeutics CEO Erik Emerson provided a strategic update on the progress of LT-100 and the growth of the ai² platform. The update emphasizes the company's commitment to discovering, advancing, and monetizing its assets. This strategic direction aims to enhance the company's clinical development priorities.

Glucotrack Announces $11.5 Million Financing

Glucotrack has announced a successful financing round, securing $11.5 million through a convertible note. This financing includes both new capital and a rollover of existing notes. The funds are intended to support the company's strategic growth initiatives.

Glucotrack Achieves Key Compliance Milestone and Advances Strategic Transformation

Glucotrack has reached a significant compliance milestone and is advancing its strategic transformation. CEO Erik Emerson expressed confidence and urgency about the company's future. This progress suggests a positive trajectory for Glucotrack as it navigates upcoming challenges.

Aug 5, 2026

▼ -12.3%on this news· ran to -33% by day 3

Glucotrack Announces $5.5 Million Financing

Glucotrack, Inc. has announced definitive agreements for approximately $5.5 million in financing. This funding includes a $2.0 million equity financing priced at $0.75 per unit and a $3.5 million follow-on investment in convertible debt. The participation of institutional investors highlights the company's potential and market confidence.

Jul 31, 2026

▼ -38.8%on this newsshared move

Lōkahi Therapeutics™ ai² Futures Lab™ Changes How Biopharma Builds a Pipeline

Glucotrack (GCTK) announced the expansion of its ai² Futures Lab™ through Lōkahi Therapeutics™. In its first year, the lab identified over 45 therapeutic opportunities with a budget of approximately $33,000, advancing five into active discussions. These opportunities represent more than $500 million in prior biopharmaceutical investment.

Jul 29, 2026

▲ +173.7%on this newsshared move

Lōkahi Therapeutics™ Advances LT-100 Development Strategy Toward Single-Injection Administration

Lōkahi Therapeutics has announced advancements in its LT-100 development strategy, aiming to reduce the administration method from 15 intradermal injections to a single subcutaneous injection. This change is expected to enhance patient compliance and convenience. The company discussed this strategy during a Type C meeting with the FDA in May 2026.

Jul 17, 2026

Glucotrack, Inc. and Lōkahi Therapeutics™ Announce Strategic Financing Support from E.F. Hutton & Co. in Connection with Their Recently Completed Business Combination and Future Capital Markets Initiatives

Glucotrack, Inc. has completed a bridge financing to support its strategic growth objectives following its business combination with Lōkahi Therapeutics. E.F. Hutton & Co. acted as the exclusive financial advisor for this financing. The funds will enhance the company's financial flexibility and support ongoing initiatives, including the advancement of Lōkahi's ai² methodology and its product development efforts.

Jul 16, 2026

UPDATE – Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform

Glucotrack, Inc. has successfully completed its strategic business combination with Lōkahi Therapeutics, establishing a publicly listed platform aimed at advancing healthcare assets. Lōkahi will control the combined entity, utilizing Glucotrack’s infrastructure to enhance growth. The transaction includes a planned private placement to bolster capital and support ongoing operations.

Jul 14, 2026

Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform

Glucotrack, Inc. has successfully completed its strategic business combination with Lōkahi Therapeutics, establishing a publicly listed platform aimed at advancing healthcare assets. Lōkahi will control the combined entity, utilizing Glucotrack's infrastructure for growth. The merger is supported by a private placement financing to bolster capital. Leadership changes have been made to guide the new organization.

Jul 8, 2026

Glucotrack Announces USPTO Notice of Allowance for Patent Application Covering Its Implantable CBGM Platform

Glucotrack, Inc. announced that the USPTO has issued a Notice of Allowance for its patent application related to its continuous blood glucose monitoring (CBGM) platform. This patent expands the protection of the company's technology as it moves towards commercialization. The CBGM system is designed for long-term, implantable glucose monitoring without wearable components, providing real-time glucose readings directly from blood.

▲ +18.9%on this news· ran to +32% by day 3shared move

May 26, 2026

GCTKConferences/Events

Glucotrack to Highlight Implantable Continuous Blood Glucose Monitoring Technology at the American Diabetes Association’s 2026 Scientific Sessions

Glucotrack, Inc. will present its implantable continuous blood glucose monitoring technology at the ADA 2026 Scientific Sessions. The presentation will focus on advancements in CGM technology that offer accurate blood measurements and extended sensor longevity. The company has submitted an Investigational Device Exemption application to the FDA, marking a significant step toward clinical studies.

May 14, 2026

Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Glucotrack, Inc. reported its first quarter 2026 financial results, highlighting the submission of an Investigational Device Exemption (IDE) application to the FDA aimed at initiating a U.S. clinical study for its implantable continuous blood glucose monitoring technology. The company noted a reduction in net loss compared to the previous year and emphasized advancements in their product development, supported by peer-reviewed studies. Additionally, Glucotrack has strengthened its financial position through debt reduction and capital funding. The company aims to initiate clinical studies in the second half of 2026.

May 7, 2026

Glucotrack Announces IDE Submission for U.S. Clinical Study of its Novel Implantable Continuous Blood Glucose Monitoring Technology

Glucotrack, Inc. has submitted an Investigational Device Exemption (IDE) application to the FDA to begin a clinical study on its continuous blood glucose monitoring technology. This submission marks a crucial step in the company's efforts to advance their implantable system designed for long-term monitoring without an on-body wearable. The technology aims to enhance convenience for diabetes patients by eliminating frequent sensor changes. Following FDA review and approval, Glucotrack intends to proceed with clinical trials to collect necessary data for regulatory approval.

▼ -7.3%on this news· ran to -21% by day 3

Apr 30, 2026

GCTKPhases

Glucotrack Announces Publication of Peer-Reviewed Study In The Journal of Diabetes Research Demonstrating Long-Term Accuracy and Stability of Continuous Blood Glucose Monitoring Technology

Glucotrack, Inc. has announced the publication of a peer-reviewed study in The Journal of Diabetes Research, showcasing the long-term accuracy and stability of its continuous blood glucose monitoring (CBGM) technology. The study, conducted on an ovine model, demonstrated an impressive Mean Absolute Relative Difference (MARD) of 6.8% and reported no adverse safety events. This research highlights the reliability of Glucotrack's system over a period of 240 days, reinforcing the company's confidence as it moves towards FDA approval. The findings are part of the growing body of evidence supporting the advantages of Glucotrack's innovative monitoring solutions for diabetes management.

Apr 21, 2026

Glucotrack Announces Publication of Peer-Reviewed Study Supporting Long-Life Sensor Design for Implantable Continuous Blood Glucose Monitoring Technology

Glucotrack, Inc. announced the publication of a peer-reviewed study in the IEEE Sensors Journal, showcasing the long-term stability of its implantable continuous blood glucose monitoring technology. This research presents the first comprehensive year-long assessment of glucose oxidase enzyme decay, bolstering the company's confidence in their device's design. The study was conducted in partnership with TTP, emphasizing the advanced development of Glucotrack’s CBGM system. The company aims to submit an Investigational Device Exemption to the FDA in the near future.

Mar 30, 2026

▼ -23.6%on this news· ran to -34% by day 1

Glucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

Glucotrack, Inc. announced its financial results for the fourth quarter and full year ending December 31, 2025, detailing significant developments in its implantable continuous blood glucose monitoring technology. The company is preparing to submit an Investigational Device Exemption to the FDA, targeting a launch for U.S. clinical trials in the second half of 2026. It also highlighted an increase in its intellectual property portfolio through newly issued patents. Despite a decrease in its annual net loss compared to the previous year, the company continues to operate with significant financial challenges, reflecting increased R&D and administrative expenses.

Mar 27, 2026